Anavex Life Sciences Stock News

AVXL earnings call for the period ending December 31, 2021.

Anavex Life Sciences Corp. (NASDAQ:AVXL) price on Wednesday, February 09, rose 5.77% above its previous days close as an upside momentum from buyers pushed the stocks value to $11.74. A look at the stocks price movement, the close in the last trading session was $11.10. The beta value (5-Year monthly) was 0.61. Turning to its Anavex Life Sciences Corp. (AVXL) Is A Possible Investment At Current Levels Read More »

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in the virtual 11 th Annual SVB Leerink Global Healthcare Conference and present on Wednesday, February 16 at 3 pm ET.

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu

NEW YORK , Feb. 9, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL ) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery Full story available on Benzinga.com

Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q1 2022 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,

Anavex Life Sciences press release (AVXL): FQ1 GAAP EPS of -$0.14.Cash and cash equivalents of $151.1 million on December 31, 2021, compared to $152.1 million on September 30, 2021.

Company to host a webcast today at 4:30 p.m. Eastern Time

Companies Reporting Before The Bell Equinor (NYSE: EQNR ) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. ICL Group (NYSE: ICL ) is expected to report quarterly earnings at $0.13 per share on revenue of $1.82 billion. Madison Square Garden (NYSE: MSGE ) is projected to report quarterly earnings at $1.00 per share on revenue of $538.98 million. Anavex Life Sciences (NASDAQ: AVXL ) is likely to report earnings for its first quarter. Orion Energy Sys (NASDAQ: OESX ) is likely to report quarterly earnings at $0.04 per share on revenue of $32.86 million. Penske Automotive Group (NYSE: PAG ) is estimated to report quarterly earnings at $3.69 per share on revenue of $6.22 billion. Mastech Digital (AMEX: MHH ) is projected to report quarterly earnings at $0.38 per share on revenue of $59.90 million. Perion Network (NASDAQ: PERI ) is projected to report quarterly earnings at $0.39 per share on revenue of $144.96 million. Ares Capital (NASDAQ: ARCC ) is estimated to report quarterly earnings at $0.49 per share on revenue of $459.14 million. Lithia Motors (NYSE: LAD ) is expected to report quarterly earnings at $10.14 per share on revenue of $6.15 billion. Cameco (NYSE: CCJ ) is expected to report quarterly earnings at $0.03 per share on revenue of $362.39 million. CDW (NASDAQ: CDW ) is expected to report quarterly earnings at $1.92 per share on revenue of $5.18 billion. Bunge (NYSE: BG ) is projected to report quarterly earnings at $2.55 per share on revenue of $13.61 billion. Yum Brands (NYSE: YUM ) is likely to report quarterly earnings at $1.09 per share on revenue of $1.88 billion. Crown Crafts (NASDAQ: CRWS ) is likely to report quarterly earnings at $0.24 per share on revenue of $18.80 million.

Most treatments for Alzheimer's disease either lead to only temporary improvements or only minimally slow down the progression of the disease. Read what makes investors positive on Anavex...

Anavex Life Sciences (NASDAQ:AVXL) is scheduled to announce Q1 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is -$0.16 (-33.3% Y/Y) and…

Anavex Life Sciences (AVXL), a clinical-stage biopharmaceutical Co., provides supplemental information on the ANAVEX®2-73 AVATAR Phase 3 trial for the treatment of adult patients with